302 related articles for article (PubMed ID: 28835193)
1. Adjustment for time-dependent unmeasured confounders in marginal structural Cox models using validation sample data.
Burne RM; Abrahamowicz M
Stat Methods Med Res; 2019 Feb; 28(2):357-371. PubMed ID: 28835193
[TBL] [Abstract][Full Text] [Related]
2. Martingale residual-based method to control for confounders measured only in a validation sample in time-to-event analysis.
Burne RM; Abrahamowicz M
Stat Med; 2016 Nov; 35(25):4588-4606. PubMed ID: 27306611
[TBL] [Abstract][Full Text] [Related]
3. Multiple imputation for systematically missing confounders within a distributed data drug safety network: A simulation study and real-world example.
Secrest MH; Platt RW; Reynier P; Dormuth CR; Benedetti A; Filion KB
Pharmacoepidemiol Drug Saf; 2020 Jan; 29 Suppl 1():35-44. PubMed ID: 31486165
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity analyses of unmeasured and partially-measured confounders using multiple imputation in a vaccine safety study.
Xu S; Clarke CL; Newcomer SR; Daley MF; Glanz JM
Pharmacoepidemiol Drug Saf; 2021 Sep; 30(9):1200-1213. PubMed ID: 33988275
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the impact of unmeasured confounding with internal validation data: an example cost evaluation in type 2 diabetes.
Faries D; Peng X; Pawaskar M; Price K; Stamey JD; Seaman JW
Value Health; 2013; 16(2):259-66. PubMed ID: 23538177
[TBL] [Abstract][Full Text] [Related]
6. Adjustments for unmeasured confounders in pharmacoepidemiologic database studies using external information.
Stürmer T; Glynn RJ; Rothman KJ; Avorn J; Schneeweiss S
Med Care; 2007 Oct; 45(10 Supl 2):S158-65. PubMed ID: 17909375
[TBL] [Abstract][Full Text] [Related]
7. The missing cause approach to unmeasured confounding in pharmacoepidemiology.
Abrahamowicz M; Bjerre LM; Beauchamp ME; LeLorier J; Burne R
Stat Med; 2016 Mar; 35(7):1001-16. PubMed ID: 26932124
[TBL] [Abstract][Full Text] [Related]
8. Robust versus consistent variance estimators in marginal structural Cox models.
Enders D; Engel S; Linder R; Pigeot I
Stat Med; 2018 Oct; 37(24):3455-3470. PubMed ID: 29888510
[TBL] [Abstract][Full Text] [Related]
9. Summarizing causal differences in survival curves in the presence of unmeasured confounding.
Martínez-Camblor P; MacKenzie TA; Staiger DO; Goodney PP; O'Malley AJ
Int J Biostat; 2020 Sep; 17(2):223-240. PubMed ID: 32946418
[TBL] [Abstract][Full Text] [Related]
10. A comparison of confounder selection and adjustment methods for estimating causal effects using large healthcare databases.
Benasseur I; Talbot D; Durand M; Holbrook A; Matteau A; Potter BJ; Renoux C; Schnitzer ME; Tarride JÉ; Guertin JR
Pharmacoepidemiol Drug Saf; 2022 Apr; 31(4):424-433. PubMed ID: 34953160
[TBL] [Abstract][Full Text] [Related]
11. Zostavax vaccine effectiveness among US elderly using real-world evidence: Addressing unmeasured confounders by using multiple imputation after linking beneficiary surveys with Medicare claims.
Izurieta HS; Wu X; Lu Y; Chillarige Y; Wernecke M; Lindaas A; Pratt D; MaCurdy TE; Chu S; Kelman J; Forshee R
Pharmacoepidemiol Drug Saf; 2019 Jul; 28(7):993-1001. PubMed ID: 31168897
[TBL] [Abstract][Full Text] [Related]
12. Validity evaluation of indirect adjustment method for multiple unmeasured confounders: A simulation and empirical study.
Byun G; Kim H; Kim SY; Kim SS; Oh H; Lee JT
Environ Res; 2022 Mar; 204(Pt A):111992. PubMed ID: 34487697
[TBL] [Abstract][Full Text] [Related]
13. How unmeasured confounding in a competing risks setting can affect treatment effect estimates in observational studies.
Barrowman MA; Peek N; Lambie M; Martin GP; Sperrin M
BMC Med Res Methodol; 2019 Jul; 19(1):166. PubMed ID: 31366331
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity analysis of treatment effect to unmeasured confounding in observational studies with survival and competing risks outcomes.
Huang R; Xu R; Dulai PS
Stat Med; 2020 Oct; 39(24):3397-3411. PubMed ID: 32677758
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics.
Schneeweiss S
Pharmacoepidemiol Drug Saf; 2006 May; 15(5):291-303. PubMed ID: 16447304
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity analysis for unmeasured confounding in a marginal structural Cox proportional hazards model.
Klungsøyr O; Sexton J; Sandanger I; Nygård JF
Lifetime Data Anal; 2009 Jun; 15(2):278-94. PubMed ID: 19109770
[TBL] [Abstract][Full Text] [Related]
17. Methods to control for unmeasured confounding in pharmacoepidemiology: an overview.
Uddin MJ; Groenwold RH; Ali MS; de Boer A; Roes KC; Chowdhury MA; Klungel OH
Int J Clin Pharm; 2016 Jun; 38(3):714-23. PubMed ID: 27091131
[TBL] [Abstract][Full Text] [Related]
18. Adjustment for unmeasured confounding through informative priors for the confounder-outcome relation.
Groenwold RHH; Shofty I; Miočević M; van Smeden M; Klugkist I
BMC Med Res Methodol; 2018 Dec; 18(1):174. PubMed ID: 30577773
[TBL] [Abstract][Full Text] [Related]
19. High-dimensional propensity score algorithm in comparative effectiveness research with time-varying interventions.
Neugebauer R; Schmittdiel JA; Zhu Z; Rassen JA; Seeger JD; Schneeweiss S
Stat Med; 2015 Feb; 34(5):753-81. PubMed ID: 25488047
[TBL] [Abstract][Full Text] [Related]
20. Testing causal effects in observational survival data using propensity score matching design.
Lu B; Cai D; Tong X
Stat Med; 2018 May; 37(11):1846-1858. PubMed ID: 29399833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
